Advanced Cancers
Conditions
Keywords
Advanced Cancers, Solid tumors, MYC amplification, CCNE1 amplification, Rb loss, FBXW7 mutation, BRCA1 mutation, BRCA2 mutation, PALB2 mutation, RAD51C mutation, RAD51D mutation, ATR mutation, ATM mutation, CHK2 mutation, Fanconi anemia
Brief summary
This research study is studying a checkpoint kinase 1 (CHK1) inhibitor as a possible treatment for advanced solid tumors that harbor genetic alterations in the homologous repair (HR) pathway, genetic alterations that indicate replication stress, or with CCNE1 amplification.
Detailed description
This is an open label, phase II, two-arm study exploring the anti-tumor activity of the CHK1 inhibitor prexasertib (LY2606368) in patients with advanced solid tumors exhibiting one of the following: 1. Replicative stress, including MYC amplification, CCNE1 amplification, Rb loss, or an FBXW7 mutation 2. An HR deficiency, including tumors with genomic or somatic mutations of BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHK2, or the Fanconi anemia pathway genes 3. A CCNE1 amplification
Interventions
DRUGLY2606368
Sponsors
Dana-Farber Cancer Institute
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Participants must have a pathologically confirmed advanced solid tumor for which standard therapy proven to provide clinical benefit does not exist or is no longer effective. * Participants must have one of the following (confirmed via targeted NextGeneration sequencing \[NGS\] using the DFCI/BWH OncoPanel or another CLIA-certified method): * For the replicative stress cohort: MYC amplification, CCNE1 amplification, Rb loss, FBXW7 mutation, or another genomic abnormality indicative of replicative stress as agreed upon with the principal investigator. OR * For the HR deficiency cohort: genomic or somatic mutation in BRCA1, BRCA2, PALB2, RAD51C, RAD51D, ATR, ATM, CHK2, the Fanconi anemia pathway genes, or another genomic or somatic mutation in a known HR gene as agreed upon with the principal investigator. * For the CCNE1 cohort: CCNE1 amplification of 6-fold or greater. Patients with borderline amplification levels may be considered following approval from the overall principal investigator. * Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan, MRI, or calipers by clinical exam. * Age ≥ 18 years. * ECOG performance status \< 2 * Participants must have adequate organ and marrow function as defined below: * Absolute neutrophil count ≥ 1.5 K/uL * Platelet count ≥ 100 K/uL * Hemoglobin ≥ 9 g/dL (with or without transfusion support) * Total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN) * AST(SGOT)/ALT(SGPT) ≤ 2.5 × institutional ULN, unless liver metastases are present and then ≤ 5 × institutional ULN is acceptable * Serum creatinine ≤ 1.5 × institutional ULN * Participants enrolling to the HR or replicative stress cohorts during Stage 1 must have disease that is amenable to biopsy and be willing to undergo a pre-treatment tumor biopsy. * The potential effects of LY2606368 use during pregnancy and lactation are not known. Nonclinical studies of LY2606368 on pregnancy and fetal development have not been performed. To minimize any potential risks, men and women with reproductive potential should use medically approved contraceptive precautions during treatment and for 3 months following the last dose of LY2606368. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and for 3 months after completion of LY2606368 administration. * Ability to understand and the willingness to sign a written informed consent document. * QTcF value of ≤ 470 msec on screening electrocardiogram (EKG)
Exclusion criteria
* Participants who have had chemotherapy, other investigational or biologic therapy, major surgery, or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the planned first dose of LY2606368 therapy. * Participants who have not recovered to eligibility levels from prior toxicity or adverse events as a result of previous treatment prior to the study. * Participants who have received prior treatment with a CHK1 inhibitor. * Participants who have received prior radiation therapy to \> 25% of the bone marrow. * Participants with known untreated brain metastases should be excluded from this clinical trial because of their poor prognosis and because they often develop progressive neurologic dysfunction that would confound the evaluation of neurologic and other adverse events. Participants with a history of brain metastases that have been treated, are no longer taking corticosteroids, and have been stable on imaging for at least one month following the end of treatment are permitted. * History of allergic reactions attributed to compounds of similar chemical or biologic composition to LY2606368. * Participants with a personal or family history of long QT syndrome. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, NYHA Class III/IV heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction within 3 months of enrollment, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant or breastfeeding females. The potential effects of LY2606368 use during pregnancy and breastfeeding are not known and LY2606368 has the potential for teratogenic or abortifacient effects. * Known HIV-positive participants are ineligible because these participants are at increased risk of lethal infections when treated with marrow-suppressive therapy. Appropriate studies will be undertaken in HIV-positive participants when indicated. * Participants enrolling to the HR or replicative stress cohort during Stage 1 may not be on anticoagulant therapy unless the treating investigator has deemed it safe to temporarily hold to facilitate the pre-treatment tumor biopsy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression-Free Rate at 4 Month | at 4 month | Progression-Free Rate defines as the percentage of participants progression-free at 4 months in all arms, by RECIST 1.1 criteria. Progression-free rate will be estimated as binomial proportion and overall survival and progression-free survival estimates and curves will be generated using the Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of Grade 4 Treatment-Related Toxicity | Assessed cycle 1 at day 1, 8, 15 and 22, and cycle 2 at day 1 and 15, from time of first dose and up to day 30 post-treatment. Median treatment duration for this study cohort was 55 day (range 6 - 539 days). | All grade 4 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEvE as reported on case report forms were counted. Incidence is the number of patients experiencing at least one treatment-related grade 4 AE of any type during the time of observation. |
| Objective Response Rate | Disease was evaluated radiologically at baseline and on treatment; Treatment continued until disease progression or unacceptable toxicity. Median treatment duration for this study cohort was 55 day (range 6 - 539 days). | The objective response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions. |
| Median Overall Survival (OS) | Participants were followed long-term for survival months from the end of treatment until death or lost to follow-up. Median (range) follow-up was 133 days (15-862 days) in this study cohort. | OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Homologous Repair (HR) Deficiency Cohort Prexasertib (LY2606368) will be administered as an IV infusion in patients with homologous repair (HR) deficiency on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour. | 8 |
| Replicative Stress Cohort Prexasertib (LY2606368) will be administered as an IV infusion in patients with advanced solid tumors exhibiting replicative stress on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour. | 10 |
| CCNE1 Amplification Cohort Prexasertib (LY2606368) will be administered as an IV infusion in patients with CCNE1 amplification on day 1 and day 15 of every 28 day cycle. Prexasertib will be given at the recommended phase 2 dose of 105 mg/m2 administered over approximately 1 hour. | 9 |
| Total | 27 |
Baseline characteristics
| Characteristic | Homologous Repair (HR) Deficiency Cohort | Replicative Stress Cohort | CCNE1 Amplification Cohort | Total |
|---|---|---|---|---|
| Age, Continuous | 61.2 years STANDARD_DEVIATION 9.5 | 55.2 years STANDARD_DEVIATION 14.2 | 61.2 years STANDARD_DEVIATION 11.6 | 59.4 years STANDARD_DEVIATION 12.1 |
| Race/Ethnicity, Customized Hispanic | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race/Ethnicity, Customized Non-Hispanic | 8 Participants | 10 Participants | 9 Participants | 27 Participants |
| Region of Enrollment United States | 8 participants | 10 participants | 9 participants | 27 participants |
| Sex: Female, Male Female | 5 Participants | 3 Participants | 5 Participants | 13 Participants |
| Sex: Female, Male Male | 3 Participants | 7 Participants | 4 Participants | 14 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk |
|---|---|---|---|
| deaths Total, all-cause mortality | 2 / 8 | 2 / 10 | 0 / 9 |
| other Total, other adverse events | 8 / 8 | 10 / 10 | 9 / 9 |
| serious Total, serious adverse events | 8 / 8 | 7 / 10 | 9 / 9 |
Outcome results
Primary
Progression-Free Rate at 4 Month
Progression-Free Rate defines as the percentage of participants progression-free at 4 months in all arms, by RECIST 1.1 criteria. Progression-free rate will be estimated as binomial proportion and overall survival and progression-free survival estimates and curves will be generated using the Kaplan-Meier method.
Time frame: at 4 month
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Homologous Repair (HR) Deficiency Cohort | Progression-Free Rate at 4 Month | >= 4 months | 25 percentage of participants |
| Homologous Repair (HR) Deficiency Cohort | Progression-Free Rate at 4 Month | < 4 months | 75 percentage of participants |
| Replicative Stress Cohort | Progression-Free Rate at 4 Month | >= 4 months | 10 percentage of participants |
| Replicative Stress Cohort | Progression-Free Rate at 4 Month | < 4 months | 90 percentage of participants |
| CCNE1 Amplification Cohort | Progression-Free Rate at 4 Month | >= 4 months | 44.4 percentage of participants |
| CCNE1 Amplification Cohort | Progression-Free Rate at 4 Month | < 4 months | 55.6 percentage of participants |
Secondary
Incidence of Grade 4 Treatment-Related Toxicity
All grade 4 adverse events (AE) with treatment attribution of possibly, probably or definite based on CTCAEvE as reported on case report forms were counted. Incidence is the number of patients experiencing at least one treatment-related grade 4 AE of any type during the time of observation.
Time frame: Assessed cycle 1 at day 1, 8, 15 and 22, and cycle 2 at day 1 and 15, from time of first dose and up to day 30 post-treatment. Median treatment duration for this study cohort was 55 day (range 6 - 539 days).
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Homologous Repair (HR) Deficiency Cohort | Incidence of Grade 4 Treatment-Related Toxicity | 5 Participants |
| Replicative Stress Cohort | Incidence of Grade 4 Treatment-Related Toxicity | 7 Participants |
| CCNE1 Amplification Cohort | Incidence of Grade 4 Treatment-Related Toxicity | 7 Participants |
Secondary
Median Overall Survival (OS)
OS based on the Kaplan-Meier method is defined as the time from study entry to death or censored at date last known alive.
Time frame: Participants were followed long-term for survival months from the end of treatment until death or lost to follow-up. Median (range) follow-up was 133 days (15-862 days) in this study cohort.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Homologous Repair (HR) Deficiency Cohort | Median Overall Survival (OS) | 108 days |
| Replicative Stress Cohort | Median Overall Survival (OS) | 328 days |
| CCNE1 Amplification Cohort | Median Overall Survival (OS) | 165 days |
Secondary
Objective Response Rate
The objective response rate (ORR) was defined as the proportion of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.
Time frame: Disease was evaluated radiologically at baseline and on treatment; Treatment continued until disease progression or unacceptable toxicity. Median treatment duration for this study cohort was 55 day (range 6 - 539 days).
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Homologous Repair (HR) Deficiency Cohort | Objective Response Rate | 0 proportion of participant |
| Replicative Stress Cohort | Objective Response Rate | 0 proportion of participant |
| CCNE1 Amplification Cohort | Objective Response Rate | 0.11 proportion of participant |